Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

OBJECTIVE: Multimodality treatment for resectable non–small cell lung cancer has long remained at a therapeutic plateau. Immune checkpoint inhibitors are highly effective in advanced non–small cell lung cancer and promising preoperatively in small clinical trials for resectable non–small cell lung c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusch, Valerie W., Nicholas, Alan, Patterson, G. Alexander, Waqar, Salama N., Toloza, Eric M., Haura, Eric B., Raz, Dan J., Reckamp, Karen L., Merritt, Robert E., Owen, Dwight H., Finley, David J., McNamee, Ciaran J., Blasberg, Justin D., Garon, Edward B., Mitchell, John D., Doebele, Robert C., Baciewicz, Frank, Nagasaka, Misako, Pass, Harvey I., Schulze, Katja, Johnson, Ann, Bunn, Paul A., Johnson, Bruce E., Kris, Mark G., Kwiatkowski, David J., Wistuba, Ignacio I., Chaft, Jamie E., Carbone, David P., Lee, Jay M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288861/
https://www.ncbi.nlm.nih.gov/pubmed/36369159
http://dx.doi.org/10.1016/j.jtcvs.2022.10.007

Ejemplares similares

Ejemplares similares